Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | TOP2A | P11388 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4449647 | 0.99 | CHRM2 (0.64) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL2920283 | 0.85 | CHRM2 (0.48) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL2923390 | 0.85 | CHRM2 (0.48) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL2914829 | 0.84 | CHRM2 (0.65) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL2920854 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL7877922 | 0.84 | CHRM2 (0.80) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL7877715 | 0.84 | CHRM2 (0.80) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL11551773 | 0.83 | CHRM2 (0.67) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4449645 | 0.83 | CHRM2 (0.64) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL31238163 | 0.83 | CHRM2 (0.79) | CHRM2CHRM1DRD2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261325-B1 | TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | claimed |
| US-7622478-B2 | 1-nitroacridine/tumor inhibitor compositions | TIWARI RAJ | 2009-11-24 | — | — | US | claimed |
| EP-1261325-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2002-12-04 | — | — | EP | claimed |
| EP-1257538-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NEW YORK MEDICAL COLLEGE | 2002-07-25 | — | — | US | claimed |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | TIWARI RAJ (US) | 2002-03-28 | — | — | US | claimed |
| WO-2001060801-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001060351-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | claimed |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| EP-1261325-B1 | TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7622478-B2 | 1-nitroacridine/tumor inhibitor compositions | TIWARI RAJ | 2009-11-24 | — | — | US | disclosed |
| US-6589961-B2 | For inhibiting metastases of a tumor in a mammal | NEW YORK MEDICAL COLLEGE | 2003-07-08 | — | — | US | disclosed |
| EP-1257538-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NEW YORK MEDICAL COLLEGE | 2002-07-25 | — | — | US | disclosed |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | TIWARI RAJ (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2001060801-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NPPA, ABCB11, ABCC9 | CHRM2 858/4885CHRM1 991/4885DRD2 1284/4885 |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | MKI67, DIAPH1, API5 | CHRM2 4669/4885CHRM1 4124/4885DRD2 4163/4885 |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | BTK, JAK2, CDK4 | CHRM2 4819/4885CHRM1 4856/4885DRD2 1246/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CHRM2 4833/4885CHRM1 4865/4885DRD2 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.